Free Newsletter
J&J job cuts hit Belgian subsidiary
Johnson & Johnson's restructuring has come home to roost in Belgium. Drug maker Janssen-Cilag, a J&J subsidiary, will slice 521 full-time and 167 part-time workers from its payroll of 4,723 in-country.
Back in July, J&J announced it would cut its global work force by up to 4,820 jobs. Contributing factors: Falling stent sales, lagging Procrit prescriptions, and expiring patents. It's the company's biggest cutback ever, amounting to about 4 percent of its payroll. An update on the restructuring is due with third-quarter earnings reports October 16.
- check out the article in the International Herald Tribune
Related Articles:
J&J makes big cuts at Alza and Scios. Report
J&J restructures pharma unit, laying off workers. Report
Big Pharma brings home the cash, slices payroll. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: